|
Age, years (SD)
|
63.0 (10.2)
|
65.0 (9.2)
|
71.5 (9.5)
|
71.3 (8.8)*
|
|
Male
|
8387/10,513 (79.8%)
|
2445/3189 (76.7%)
|
830/1332 (62.3%)
|
518/838 (61.8%)*
|
|
Mean body-mass index, kg/m2 (SD)
|
27.65 (4.3)
|
29.59 (5.0)
|
28.01 (4.5)
|
29.91 (5.0)*
|
|
Medical history
|
|
Insulin-dependent diabetes mellitus
|
0/10,513 (0.0%)
|
869/3155 (27.3%)
|
0/1332 (0.0%)
|
352/836 (42.0%)
|
|
Hypertension
|
7047/10,471 (67.3%)
|
2721/3185 (85.4%)
|
1118/1329 (84.1%)
|
770/838 (91.9%)*
|
|
Hypercholesterolemia
|
6771/10,196 (64.4%)
|
2421/3085 (75.9%)
|
879/1286 (66.0%)
|
634/813 (75.7%)*
|
|
Current smoker
|
3135/10,513 (29.8%)
|
686/3189 (21.5%)
|
207/1332 (15.5%)
|
110/838 (13.1%)*
|
|
Previous stroke
|
209/10,501 (2.0%)
|
120/3182 (3.8%)
|
48/1330 (3.6%)
|
44/838 (5.3%)*
|
|
Previous peripheral vascular disease
|
480/10,433 (4.6%)
|
273/3158 (8.6%)
|
121/1317 (9.1%)
|
126/826 (15.0%)*
|
|
Chronic obstructive pulmonary disease
|
485/10,474 (4.6%)
|
179/3174 (5.6%)
|
86/1327 (6.5%)
|
69/828 (8.2%)*
|
|
Previous myocardial infarction
|
2265/10,487 (21.5%)
|
815/3176 (25.6%)
|
344/1330 (25.8%)
|
269/835 (32.1%)*
|
|
Previous PCI
|
3107/10,504 (29.6%)
|
1249/3186 (39.2%)
|
471/1331 (35.4%)
|
372/838 (44.4%)*
|
|
Previous CABG
|
477/10,506 (4.5%)
|
266/3185 (8.4%)
|
91/1331 (6.8%)
|
107/838 (12.8%)*
|
|
Previous bleeding
|
59/10,504 (0.6%)
|
18/3181 (0.6%)
|
15/1331 (1.1%)
|
6/838 (0.7%)
|
|
Clinical presentation
|
|
Stable coronary artery disease
|
5298/10,513 (50.4%)
|
1913/3189 (60.0%)
|
690/1332 (51.8%)
|
514/838 (61.3%)
|
|
Acute coronary syndrome
|
5215/10,513 (49.6%)
|
1276/3189 (40.0%)
|
642/1332 (48.2%)
|
324/838 (38.7%)
|
|
Complex PCI
|
2976/10,513 (28.3%)
|
934/3189 (29.3%)
|
377/1332 (28.3%)
|
263/838 (31.4%)
|
|
Multivessel PCI
|
2216/10,513 (21.1%)
|
671/3189 (21.0%)
|
282/1332 (21.2%)
|
189/838 (22.6%)
|
|
Lesion treated ≥ 3
|
851/10,513 (8.1%)
|
266/3189 (8.3%)
|
113/1332 (8.5%)
|
68/838 (8.1%)
|
|
Stent implanted ≥ 3
|
1793/10,513 (17.1%)
|
568/3189 (17.8%)
|
235/1332 (17.6%)
|
162/838 (19.3%)
|
|
Bifurcation PCI with ≥ 2 stents
|
323/10,513 (3.1%)
|
88/3189 (2.8%)
|
31/1332 (2.3%)
|
28/838 (3.3%)
|
|
Total stent length >60 mm
|
1346/10,513 (12.8%)
|
437/3189 (13.7%)
|
180/1332 (13.5%)
|
106/838 (12.7%)
|
|
Total Stent Length (SD)
|
35.2 (25.1)
|
36.0 (25.2)
|
35.7 (25.8)
|
36.3 (26.2)
|
|
Medications on discharge
|
|
ACE-inhibition and/or ARB
|
6346/10,450 (60.4%)
|
1986/3162 (62.3%)
|
730/1320 (54.8%)
|
457/826 (54.5%)
|
|
Beta-blockade
|
8194/10,452 (77.9%)
|
2577/3163 (80.8%)
|
1069/1321 (80.3%)
|
669/826 (79.8%)
|
|
Statin
|
9718/10,459 (92.4%)
|
2916/3168 (91.4%)
|
1212/1322 (91.0%)
|
764/827 (91.2%)
|
|
Paris bleeding risk score [31] (IQR)
|
3 (2,4)
|
3 (2,4)
|
6 (5,7)
|
6 (5,7)*
|
|
Paris thrombotic risk score (IQR)
|
2 (0,4)
|
3 (2,4)
|
4 (2,7)
|
5 (4,7)*
|
|
Paris bleeding risk score ≥ 8
|
100/10,039 (1.0%)
|
41/3060 (1.3%)
|
269/1288 (20.9%)
|
189/803 (23.5%)*
|
|
Paris thrombotic risk score ≥ 5
|
140/10,506 (1.3%)
|
655/3185 (20.8%)
|
243/1331 (18.3%)
|
615/838 (73.4%)*
|
|
PRECISE DAPT score [15] (IQR)
|
14 (9,19)
|
15 (10,20)
|
27 (23,32)
|
29 (24,34)*
|
|
PRECISE DAPT score ≥ 25
|
731/9849 (7.4%)
|
323/3007 (10.7%)
|
846/1266 (66.8%)
|
567/799 (71.0%)*
|
|
Antiplatelet therapy
|
|
Reference treatment strategy
|
5297/10,513 (50.4%)
|
1575/3189 (49.4%)
|
662/1332 (49.7%)
|
410/838 (48.9%)
|
|
Experimental treatment strategy
|
5216/10,513 (49.6%)
|
1614/3189 (50.6%)
|
670/1332 (50.3%)
|
428/838 (51.1%)
|
